Navigation Links
NuVasive to Host Investor Reception on September 11, 2007
Date:9/7/2007

Waldorf=Astoria Hotel New York City 5:30-7:30 p.m. (ET)

SAN DIEGO, Sept. 7 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that it will host an investor reception for institutional investors and analysts at the Waldorf=Astoria Hotel in New York City on Tuesday, September 11, 2007, from 5:30 p.m. to 7:30 p.m. ET.

The reception will be hosted by NuVasive and includes presentations by senior management and top academic and private leading physicians from New York, Washington, DC and Texas. The physicians will participate in an interactive surgeon panel presentation covering key clinical updates, including an update from a surgeon participating in the NeoDisc clinical trial, as well as physician experience with XLIF(R) and new products launched during the first half of 2007 (SpheRx(R) II, XLP(TM) Lateral Plate and Formagraft(R)). Senior management and guest physicians will also participate in a question and answer session.

NuVasive senior management at the reception will include:

* Alex Lukianov, Chairman and Chief Executive Officer

* Keith Valentine, President and Chief Operating Officer

* Kevin O'Boyle, Executive Vice President and Chief Financial Officer

* Pat Miles, Executive Vice President of Marketing and Development

* Jeff Rydin, Senior Vice President, U.S. Sales

* Jason Hannon, Senior Vice President and General Counsel

Participants in the physician panel will include:

* Andrew Cappuccino, MD, Director Buffalo Spine Surgery and Assistant

Clinical Professor at SUNY, Buffalo, NY

* Randall Dryer, MD, Attending Orthopedic Surgeon, Central Texas Spine

Institute, Austin, TX

* Eric Elowitz, MD, Attending Neurosurgeon at St. Luke's-Roosevelt and

Beth Israel Hospitals and Assistant Professor of Neurological
'/>"/>

SOURCE NuVasive, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Venture Investors early-stage fund grows to $115 million
2. Investor warns of angel-venture funding gap
3. Brazilian bio-industry should impress American investors
4. Investors raise $25 million for biodiesel plant
5. Bio-energy and cleantech grab attention of investors
6. Venture Investors to open Michigan office
7. Early-stage executives hear from investors
8. Commerce qualifies seven for investor tax credits
9. Investor links East Coast funds to Midwest tech
10. Angel investors commit $12.7B in first half of `06
11. Wisconsin investors the lifeblood of New Jersey biotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... development and commercialization of a once-daily, oral therapy for ... announced financial results for the period ended June 30, ... , Reported cash and cash equivalents totaling $37.4 million ... 31, 2013.  , Reported a net loss of ...
(Date:7/24/2014)... 24, 2014 -- A novel combination of microscopy and ... Energy,s Oak Ridge National Laboratory an unprecedented look at ... physical and electrochemical properties. , The research team ... the surface of a perovskite manganite, a complex material ... avenue to understand surface behavior could benefit researchers who ...
(Date:7/24/2014)... equipment, trained personnel, and detection dogs to safeguard ... A revolutionary new electronic chip with nano-sized chemical ... easier. , The groundbreaking nanotechnology-inspired sensor, devised by ... School of Chemistry and Center for Nanoscience and ... picks up the scent of explosives molecules better ...
(Date:7/24/2014)... DUBLIN , July 24, 2014 ... the "Global Cell Culture Market 2014-2018" report ... Cell culture is the in vitro ... such as research, cell studies, and biopharmaceutical production. Cell ... vaccine production. Cell culture instruments and cell culture consumables ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6ORNL study reveals new characteristics of complex oxide surfaces 2Nano-sized chip 'sniffs out' explosives far better than trained dogs 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2
... , , , ... company Viral Genetics (Pink Sheets: VRAL) has formed a wholly ... advance a technology developed by University of Colorado Professor M. ... blocking a tumor cell,s ability to generate energy from glucose ...
... SALEM, N.H., Aug. 7 ALPCO Diagnostics has introduced a ... I SA kit that facilitates the testing process ... other methods for determining mouse HMW adiponectin and was first introduced in ... Tsukuba Research Institute in the journal Clinica Chimica Acta in February 2009. ...
... , RANCHO CORDOVA, Calif., Aug. 6 ... supplier of innovative products for processing and storing adult stem cells, ... of SpineSmith, LLC, related to the Company,s bone marrow products, MXP(TM) ... leading distributor of orthopedic products, based in Texas. , ...
Cached Biology Technology:Viral Genetics Creates Subsidiary to Develop Cancer Therapy 2Viral Genetics Creates Subsidiary to Develop Cancer Therapy 3Viral Genetics Creates Subsidiary to Develop Cancer Therapy 4ALPCO Introduces a Mouse HMW and Total Adiponectin ELISA 2ThermoGenesis Announces Expanded Collaboration With Celling Technologies 2ThermoGenesis Announces Expanded Collaboration With Celling Technologies 3ThermoGenesis Announces Expanded Collaboration With Celling Technologies 4
(Date:7/27/2014)... from over 18,000 patients, scientists have identified more ... Parkinson,s disease, including six that had not been ... Genetics , was partially funded by the National ... working in NIH laboratories. , "Unraveling the genetic ... multiple mechanisms involved in this complex disease, and ...
(Date:7/25/2014)... WASHINGTON (July 24, 2014)The link between autism and ... the puzzle of the disease, and is largely ... Foundation Autism Research Initiative (SFARI), George Washington University ... to offer truly integrative and in-depth answers to ... research. , LaMantia, professor of pharmacology and ...
(Date:7/25/2014)... opened the way for the development of new lines of ... barley production is second only to wheat with 7-8 million ... important diseases of barley. , Senior Research Scientist Dr Alan ... on the cell walls of barley plants that block the ... by the ARC Centre of Excellence in Plant Cell Walls ...
Breaking Biology News(10 mins):NIH scientists find 6 new genetic risk factors for Parkinson's 2GW researcher receives grant to answer the how and why of autism during development 2New hope for powdery mildew resistant barley 2
... a way, nanotubes are nature’s smallest candles. , These tiny ... small that it takes about 100,000 laid side-by-side to span ... five years, scientists have discovered that some individual nanotubes are ... light. Some glow brightly. Others glow dimly. Some glow in ...
... specialists associated with the Neuroscience Institute at the ... the ability to incorporate—in real time—two high-tech imaging ... functional abilities of patients who undergo brain surgery. ... UC colleagues are among the first in the ...
... team has discovered a gene that, when mutated, causes one ... Scientists at the University of Leeds, working in collaboration with ... which is essential to photoreceptors in the eye, the cells ... to be linked to Leber’s congenital amaurosis (LCA), comes at ...
Cached Biology News:Brightening prospects of using fluorescent nanotubes in medical applications 2Brightening prospects of using fluorescent nanotubes in medical applications 3Dual-imaging technique useful before -- and during -- brain surgery 2'Lucky 13' as new gene discovery offers further hope for childhood blindness 2'Lucky 13' as new gene discovery offers further hope for childhood blindness 3